FY2025 · ended Dec 31, 2025 · Revenue $6.22B, -2.9% YoY · Filed Feb 24, 2026
Organon & Co. (OGN) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $6.2 billion and net income of $187.0 million. Free cash flow was $538.0 million. As of Sep 30, 2026 it held $1.5 billion in cash and investments and $8.6 billion in total debt.
Revenue (TTM)
$6.10B
-3.2% vs year-ago TTM
Net income (TTM)
$213.00M
-57.5% vs year-ago TTM
Operating cash flow (TTM)
$843.00M
-11.2% vs year-ago TTM
Free cash flow (TTM)
$675.00M
-13.1% vs year-ago TTM
EPS (TTM)
$0.80
-58.5% vs year-ago TTM
Dividend per share (TTM)
$0.08
-86.7% vs year-ago TTM
Shares outstanding
260.32M
+0.9% vs prior year
Net cash
$-7.10B
as of Sep 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- OGN (NYSE)
- Fiscal year ends
- December 31
- Headquarters
- Jersey City, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1821825
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $6.2B | $6.4B | $6.3B | $6.2B | $6.3B |
| Net income | $187.0M | $864.0M | $1.0B | $917.0M | $1.4B |
| Diluted EPS | $0.72 | $3.33 | $3.99 | $3.59 | $5.31 |
| Operating cash flow | $700.0M | $939.0M | $799.0M | $858.0M | $2.2B |
| Free cash flow | $538.0M | $764.0M | $548.0M | $662.0M | $2.0B |
| Total assets | $12.9B | $13.1B | $12.1B | $11.0B | $10.7B |
| Total liabilities | $12.1B | $12.6B | $12.1B | — | — |
| Stockholders' equity | $752.0M | $472.0M | -$70.0M | -$892.0M | -$1.5B |
| Cash and investments | $574.0M | $675.0M | $693.0M | $706.0M | $737.0M |
| Total debt | $8.8B | $9.0B | $8.9B | $9.1B | $9.4B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Oct 30, 2026 | Oct 30, 2026 |
| 10-Q | Quarterly report | Oct 30, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 31, 2026 | Jul 31, 2026 |
| 10-Q | Quarterly report | Jul 31, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jul 23, 2026 | Jul 23, 2026 |
| 8-K |
Current report
Other events
|
Jul 17, 2026 | Jul 17, 2026 |
All 461 Organon & Co. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.